{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:55:22Z","timestamp":1776131722342,"version":"3.50.1"},"reference-count":46,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MA 9302\/2\u20131"],"award-info":[{"award-number":["MA 9302\/2\u20131"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["70113496"],"award-info":[{"award-number":["70113496"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["MA 9302\/2\u20131"],"award-info":[{"award-number":["MA 9302\/2\u20131"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113496"],"award-info":[{"award-number":["70113496"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>B cell acute lymphoblastic leukemia (B-ALL) is characterized by an accumulation of malignant precursor cells. Treatment consists of multiagent chemotherapy followed by allogeneic stem cell transplantation in high-risk patients. In addition, patients bearing the BCR-ABL1 fusion gene receive concomitant tyrosine kinase inhibitor (TKI) therapy. On the other hand, monoclonal antibody therapy is increasingly used in both clinical trials and real-world settings. The introduction of rituximab has improved the outcomes in CD20 positive cases. Other monoclonal antibodies, such as tafasitamab (anti-CD19), obinutuzumab (anti-CD20) and epratuzumab (anti-CD22) have been tested in trials (NCT05366218, NCT04920968, NCT00098839). The efficacy of monoclonal antibodies is based, at least in part, on their ability to induce antibody-dependent cellular cytotoxicity (ADCC). Combination treatments, e.g., chemotherapy and TKI, should therefore be screened for potential interference with ADCC. Here, we report on in vitro data using BCR-ABL1 positive and negative B-ALL cell lines treated with rituximab and TKI. NK cell activation, proliferation, degranulation, cytokine release and tumor cell lysis were analyzed. In contrast to ATP site inhibitors such as dasatinib and ponatinib, the novel first-in-class selective allosteric ABL myristoyl pocket (STAMP) inhibitor asciminib did not significantly impact ADCC in our settings. Our results suggest that asciminib should be considered in clinical trials.<\/jats:p>","DOI":"10.3390\/cancers16071288","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T11:05:33Z","timestamp":1711451133000},"page":"1288","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4513-2367","authenticated-orcid":false,"given":"Samuel J.","family":"Holzmayer","sequence":"first","affiliation":[{"name":"Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Cluster of Excellence iFIT (EXC 2180), Image-Guided and Functionally Instructed Tumor Therapies, Eberhard Karls University, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-0167","authenticated-orcid":false,"given":"Joseph","family":"Kauer","sequence":"additional","affiliation":[{"name":"Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Interfaculty Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69117 Heidelberg, Germany"},{"name":"European Molecular Biology Laboratory (EMBL), 69116 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Mauermann","sequence":"additional","affiliation":[{"name":"Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Cluster of Excellence iFIT (EXC 2180), Image-Guided and Functionally Instructed Tumor Therapies, Eberhard Karls University, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6973-3531","authenticated-orcid":false,"given":"Tobias","family":"Roider","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69117 Heidelberg, Germany"},{"name":"European Molecular Biology Laboratory (EMBL), 69116 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2920-3894","authenticated-orcid":false,"given":"Melanie","family":"M\u00e4rklin","sequence":"additional","affiliation":[{"name":"Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Cluster of Excellence iFIT (EXC 2180), Image-Guided and Functionally Instructed Tumor Therapies, Eberhard Karls University, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"ref_1","first-page":"3977","article-title":"Redefining ALL classification: Toward detecting high-risk ALL and implementing precision medicine","volume":"125","author":"Hunger","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Komorowski, L., Fidyt, K., Patkowska, E., and Firczuk, M. (2020). Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage\u2014Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165776"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1002\/cam4.2153","article-title":"Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia","volume":"8","author":"Chang","year":"2019","journal-title":"Cancer Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1158\/1538-7445.AM2022-3324","article-title":"Optimizing the therapeutic potential of tyrosine kinase inhibitors in chemo-immunotherapy of B-cell acute lymphoblastic leukemia involving rituximab","volume":"82","author":"Domka","year":"2022","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: Addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.leukres.2019.02.009","article-title":"Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"79","author":"King","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1080\/10428194.2021.1966787","article-title":"Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"62","author":"Zerbit","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Bassan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome\u2013negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1002\/cncr.33796","article-title":"A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed\/refractory B-precursor cell acute lymphoblastic leukemia","volume":"127","author":"Klisovic","year":"2021","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1535-7163.MCT-21-0058","article-title":"Evaluation of preclinical activity of isatuximab in patients with acute lymphoblastic leukemia","volume":"20","author":"Wang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/pbc.25454","article-title":"Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children\u2019s Oncology Group (COG) study ADVL04P2","volume":"62","author":"Raetz","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/ijc.25233","article-title":"The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity","volume":"127","author":"Salih","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","article-title":"Immunological off-target effects of imatinib","volume":"13","author":"Zitvogel","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/blood-2019-125138","article-title":"A phase I study of asciminib (ABL001) in combination with dasatinib and prednisone for untreated BCR-ABL1-positive ALL in older adults","volume":"134","author":"Luskin","year":"2019","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome\u2013positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of bosutinib","volume":"55","author":"Abbas","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_23","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","first-page":"4055","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000509639","article-title":"Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"65","author":"Menna","year":"2020","journal-title":"Chemotherapy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: Longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/cts.13252","article-title":"Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants","volume":"15","author":"Hoch","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood-2023-184647","article-title":"Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present","volume":"142","author":"Eadie","year":"2023","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2352-3026(22)00038-2","article-title":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): A phase 3, multicentre, randomised controlled trial","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.18632\/oncotarget.13643","article-title":"Novel Src\/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src\/Abl signaling","volume":"8","author":"Bieerkehazhi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1582-4934.2009.00902.x","article-title":"Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo","volume":"14","author":"Ballinger","year":"2010","journal-title":"J. Cell Mol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood-2004-05-1851","article-title":"Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: Implications for CML","volume":"104","author":"Pollock","year":"2004","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","article-title":"Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies","volume":"10","author":"Gozgit","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1128\/IAI.00533-13","article-title":"Requirement and redundancy of the Src family kinases Fyn and Lyn in perforin-dependent killing of Cryptococcus neoformans by NK cells","volume":"81","author":"Oykhman","year":"2013","journal-title":"Infect. Immun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/0008-5472.CAN-19-2332","article-title":"Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling","volume":"80","author":"Tan","year":"2020","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4049\/jimmunol.1801418","article-title":"Effects of PI3K Inhibition on Afucosylated Antibody-Driven FcgammaRIIIa Events and Phospho-S6 Activity in NK Cells","volume":"203","author":"Romeo","year":"2019","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_43","first-page":"939","article-title":"Concomitant use of a dual Src\/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL","volume":"137","author":"Leonard","year":"2021","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s00432-022-04039-5","article-title":"BCR:: ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro","volume":"148","author":"Kauer","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","article-title":"Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia","volume":"17","author":"Assi","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00262-022-03361-8","article-title":"Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib","volume":"72","author":"Karow","year":"2023","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1288\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:19:00Z","timestamp":1760105940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16071288"],"URL":"https:\/\/doi.org\/10.3390\/cancers16071288","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]}}}